Immix Biopharma, Inc. (IMMX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Immix Biopharma reported revenue of $0. Net income was -$29.4M, or -$0.89 per diluted share. Operating activities generated -$23.9M of cash, leaving -$24.7M of free cash flow. At fiscal year end, Immix Biopharma held $104.8M in total assets against $11.0M in total liabilities, including $93.9M of cash and equivalents.
Open the full interactive Immix Biopharma financials → Quarterly statements, key ratios, valuation history and price charts.
Immix Biopharma Key Stats
| Share Price | $8.69 |
|---|---|
| Market Cap | $554.2M |
| 52-Week Range | $2.48 – $14.47 |
| Shares Outstanding | 63.8 million (basic, 2026 Q2) |
Immix Biopharma Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M |
| Pre-Tax Income | -$24.4M | -$8.2M | -$15.6M | -$21.7M | -$29.4M |
| Income Tax | $6,013 | $10,268 | $26,415 | $41,037 | $37,724 |
| Net Income | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| Diluted EPS | -$6.64 | — | -$0.89 | -$0.76 | -$0.89 |
Immix Biopharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.6M | -$10.7M | -$10.1M | -$11.6M |
| Diluted EPS | -$0.24 | -$0.32 | -$0.18 | -$0.18 |
Immix Biopharma Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $17.6M | $13.4M | $17.5M | $17.7M | $93.9M |
| Current Assets | $18.2M | $14.9M | $19.8M | $20.2M | $101.2M |
| Total Assets | $18.2M | $14.9M | $19.9M | $22.9M | $104.8M |
| Current Liabilities | $202,039 | $1.3M | $3.7M | $8.7M | $10.1M |
| Total Liabilities | $202,039 | $1.7M | $3.7M | $9.7M | $11.0M |
| Shareholders' Equity | $18.0M | $13.2M | $16.4M | $13.3M | $93.8M |
Immix Biopharma Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$1.6M | -$7.4M | -$11.4M | -$14.6M | -$23.9M |
| Cash From Investing | -$802 | — | -$52,089 | -$1.2M | -$7.2M |
| Cash From Financing | $18.8M | $3.2M | $15.5M | $15.9M | $107.4M |
| Free Cash Flow | -$1.6M | -$7.4M | -$11.4M | -$15.8M | -$24.7M |
Figures from Immix Biopharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Immix Biopharma financials page for every line item.
Immix Biopharma Company Profile
| Ticker | IMMX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Los Angeles, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001873835 |
Frequently Asked Questions
What was Immix Biopharma's revenue in fiscal 2025?
Immix Biopharma (IMMX) reported revenue of $0 for fiscal 2025.
What is Immix Biopharma's annual revenue history?
Immix Biopharma's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Immix Biopharma's net income in fiscal 2025?
Immix Biopharma reported net income of -$29.4M for fiscal 2025.
What was Immix Biopharma's earnings per share (EPS) in fiscal 2025?
Immix Biopharma's diluted EPS was -$0.89 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Immix Biopharma generate in fiscal 2025?
Immix Biopharma generated -$24.7M of free cash flow in fiscal 2025.
What was Immix Biopharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Immix Biopharma reported revenue of $0.
How many shares of Immix Biopharma are outstanding?
Immix Biopharma reported a weighted average of 63.8 million basic shares outstanding in 2026 Q2.
What is Immix Biopharma's market cap?
Based on its latest closing price, Immix Biopharma (IMMX) has a market capitalization of about $554.2M.
When does Immix Biopharma's fiscal year end?
Immix Biopharma's fiscal year end, as registered with the SEC, is December 31.
Where is Immix Biopharma headquartered?
Immix Biopharma lists its business address in Los Angeles, California in its SEC filings.